**Title:** Screening for Hepatitis B Virus (HBV) Infection (CAG-00447N)

**Decision:** The Centers for Medicare & Medicaid Services (CMS) has determined that the evidence is sufficient to conclude that screening for Hepatitis B Virus (HBV) infection, is reasonable and necessary for the prevention or early detection of an illness or disability and is appropriate for individuals entitled to benefits under Part A or enrolled under Part B.

What this means: Screening for HBV infection with the appropriate U.S. Food and Drug Administration (FDA) approved/cleared laboratory tests, used consistent with FDA approved labeling and in compliance with the Clinical Laboratory Improvement Act (CLIA) regulations, when ordered by the beneficiary's primary care physician or practitioner within the context of a primary care setting, and performed by an eligible Medicare provider for these services, for beneficiaries who meet specific criteria is a Medicare covered.

**Effective:** 9/28/16

For more information, contact Customer Services at the phone number on your member ID card.

This announcement can be found at: Screening for Hepatitis B Virus (HBV) Infection

H2456\_022411\_11 DHS Approved (02252011) CMS Approved (04062011) Y0120 B G 031016 1 IA (03102016)

U4174 (10/16)